Core Points - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI-enabled bio-manufacturing, green chemicals and new materials, future food, and future agriculture [3][4] - The conference aims to explore the development trends of the bio-manufacturing industry during the 14th Five-Year Plan, innovations driven by AI, and the technologies and products that will sustain the industry's vitality [3][4] - Various activities will take place during the conference, including a youth forum, high-level discussions, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [3][4][9] Conference Overview - The conference is organized by Ningbo Detai Zhongyan Information Technology Co., Ltd. and supported by several academic and industry organizations, including Peking University and the China Society of Bioengineering [4][5] - The agenda includes multiple forums and discussions on topics such as green chemicals, AI in bio-manufacturing, and future food and agriculture [7][8][9] Key Activities - Day 1 features a high-level discussion on bio-manufacturing industry trends and a youth forum to discover innovative outcomes in bio-manufacturing [9][12] - Day 2 includes an opening ceremony, macro forums on the bio-manufacturing industry, and specialized forums on green chemicals and AI empowerment [8][9][18] - Day 3 focuses on future food and agriculture, with discussions on new functional sugars and probiotics [27][28][29] Industry Insights - The conference will release the "China Synthetic Biology Industry Distribution Map (2025 Edition)" and a list of over 500 representative enterprises in the bio-manufacturing sector [54][55] - The event aims to facilitate technology transfer, product scaling, and talent acquisition within the bio-manufacturing industry [3][4]

Group 1 - Tianjin Hesheng Biotechnology Co., Ltd. completed a Pre-A round financing of several tens of millions, led by Bohai Chuangfu Securities Investment Co., Ltd. with participation from Tianjin Haitai Haihe Biomedical Industry Fund and Tianjin Kechuang Angel Investment Co., Ltd. [1] - The company was established in August 2023 and is one of the major technology transfer enterprises of Nankai University, focusing on the functional application research of human milk oligosaccharides (HMOs) [1]. - The founder of the company is Professor Liu Bin from Nankai University, who established the first domestic biosynthesis technology for human milk oligosaccharides in 2016, achieving a breakthrough from "0 to 1" [1]. Group 2 - The company has obtained invention patents for various industrial strains including 2'-FL, 3-FL, 3'-SL, 6'-SL, LNT, LNnT, DFL, and LNFP I, and plans to apply for more than ten additional invention patents [1]. - The HMOs produced by the company have completed small-scale, pilot, and large-scale production, with a product purity of 98.98%, significantly exceeding domestic and international quality standards [1]. - The registered capital of the company is 9.3563 million, with major shareholders including FENG. LU (38.01%), Wang Shuo (16.16%), and Tianjin Nankai University Asset Management Co., Ltd. (10.69%) [2].